1Besarab A, Bohon WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin[ J]. N Engl J Med,1998,339(9) :584 -590.
2Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease [J]. New Engl J Med,2006, 355(20) :2085 -2098.
3Drueke TB, Locatelli F, Clyne N, et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia[ J]. New Engl J Med ,2006,355 (20) :2071 - 2084.
4NKF - DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure: update 2000. IV. Administration of epoetin[ J 1. Am J Kidney Dis, 2001 ; 37( Suppl 1 ) :S182 - S238.
5Priyadarshi A, Shapiro JI. Erythropoietin Resistance in the Treatment of the Anemia of Chronic Renal Failure[ J]. Semin Dial,2006, 19(4) :273 -278.
6Ehrenreich H, Hasselblatt M. Erythropoietin therapy for acute stroke is both safe and beneficial [ J ]. Mol Med, 2002, 8 ( 8 ) : 495 - 505.
7Silverberg DS, Wexler D. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study[J]. J Am Coll Cardiol,2001, 37(7) :1775 -1780.
8Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model [ J ]. Nephrol Dial Transplant, 2006,21 (2) :330-336.
9MacdougaU IC, Robson R, Opatma S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C. E. R. A. ) in patients with chronic kidney disease [ J ]. Clin J Am Soc Nephrol,2006,1 (6) :1211 - 1215.
10Woodburn KW, Fan Q. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by anfierythropoietin antibodies in a rat pure red cell aplasia model [ J ]. Exp Hematol, 2007,35 ( 8 ) : 1201 - 1208.
